Is this biotech stock on its way to a 50% surge?

An article about the biotech company Argenx, traded at a market cap of approximately $60 billion. Leading analysts, including Wells Fargo and UBS, set target prices of up to $1,415, representing a profit potential of over 50%. The last quarter showed sales of $1.5 billion, a 60% jump compared to the same quarter last year.

An article about the biotech company Argenx, traded at a market cap of approximately $60 billion. Leading Wall Street analysts estimate the stock could surge up to 50% within a year, with target prices of up to $1,415 from Wells Fargo and $1,400 from UBS. Out of 21 analysts, 20 recommended 'Buy' and one 'Hold'. The last quarter showed global sales of $1.5 billion, a 60% jump compared to the same quarter last year. The main growth drivers are the treatments Vyvgart and Vyvgart Hytrulo. The company aims to expand approvals for additional diseases and reported positive results in a Phase 3 trial. However, the article notes that success is not guaranteed and depends on future clinical trial results.

Is this biotech stock on its way to a 50% surge?